Abbott is cueing up launch after launch for 2020, while J&J is pinning its device hopes to robotic surgery.
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
Belantamab’s registrational Dreamm-2 study comes up short of an earlier trial and, more importantly, now seriously lags competitors’ data.
Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
As numerous Car-T therapies battle it out in the burgeoning BCMA field, Ash shows that the real threat could come from elsewhere.
This year’s Ash features numerous duelling anti-BCMA therapies in multiple myeloma, and the first clinical data for JNJ-4528 impress.